CClinicalTrials.gg
CompletedNCT04259983Updated Dec 6, 2023

Investigation of Relationship Between Vascular Functions, Exercise Capacity, and Respiratory Functions in CF

An observational study in Cystic Fibrosis, sponsored by Hacettepe University. Completed at 1 site in Turkey. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Hacettepe University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
60
Ages
10 Years to 18 Years
Sex
All
01

Study summary

In the literature, there is no study that evaluates the endothelial function and arterial stiffness together and investigates its relationship with exercise capacity and respiratory functions in children with CF of different obstruction severities. Therefore, the aim of this study is to investigate and compare microvascular (endothelium), macrovascular (arterial stiffness) functions in children with CF of different obstruction severities, and to investigate the relationship between micro and macrovascular functions and exercise capacity and respiratory functions in children with CF of different obstruction severities.

Read the detailed description

Cystic fibrosis (CF) is a rare disease with congenital deterioration in mucociliary clearance that causes recurrent or chronic rhinosinusitis, airway infection and bronchiectasis in pediatric age. There are pulmonary genetic disorders associated with inflammation. Children with CF have been shown to have vascular endothelial dysfunction compared to healthy children. Very young children with CF have been reported to have increased arterial stiffness and some decrease in right-left ventricular function. In another study on the subject, it was found that stiffness of the great arteries increased in children with CF; The change in arterial compliancy has been shown to be significant in childhood. The increase in arterial stiffness is associated with systemic inflammation, regardless of blood pressure or diabetes. Hemodynamic changes have been reported in the presence of systemic inflammation in children with CF. Exercise peak workload in children with CF is known to be associated with endothelial dysfunction. It is not known how exercise capacity is affected by endothelial dysfunction and arterial stiffness in CF patients of varying severity. In the literature, there are no studies comparing endothelial function, arterial stiffness and its effect on exercise capacity and pulmonary functions in CF children; this subject is open to research. The aim of this study was to investigate and compare microvascular (peripheral endothelial), macrovascular (arterial stiffness) functions in children with CF and to investigate the relationship of micro and macrovascular functions with exercise capacity and pulmonary functions in children with CF of different obstruction severities.

02

Conditions studied

  • Cystic Fibrosis

Keywords

  • Endothelial Dysfunction
  • Arterial Stiffness
  • Exercise Capacity
  • Respiratory Functions
  • Children
03

In context

Cystic Fibrosis

1,581 studies on the registry are indexed under Cystic Fibrosis; 190 are open to participants now.

This study's enrollment of 60 is below the median of 85 across 482 observational studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

Hacettepe University is the lead sponsor of 983 studies on the registry; 212 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children who are diagnosed with Cystic Fibrosis with different obstruction severity at Hacettepe University Faculty of Medicine, Department of Pediatric Chest Diseases and who reffered to the Cardiopulmonary Rehabilitation Unit for Physiotherapy also who are willing to participate in the study will be include in the study.

Inclusion criteria

  • Being clinically stable
  • To be cooperated in evaluations to be made
  • Forced expiratory volume in the first second (FEV1)> 40%
  • No exacerbation in the past three months
  • Regular medication for the past 12 months
  • No medication changes for at least three weeks

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular disease
  • Hypertension
  • Diabetes
  • Pulmonary hypertension
  • Smoking
  • Resting oxygen saturation (SpO2) \<92%
  • Using vasoactive drugs (nitrates, b-blockers, angiotensin-converting enzyme inhibitors, etc.)
  • Using oral steroids
  • Undergoing lung surgery
  • Being a highly orthopedic, neurological disease
  • Injury to the lower extremity such as injury, sprain, or fracture in the past six months
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
60 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Patients with CF with normal obstruction severity

    In CF children with normal obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.

    Other: Maximal exercise test · Other: Endothelial dysfunction assessment · Other: Arterial stiffness assessment

  • Patients with CF with mild obstruction severity

    In CF children with mild obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.

    Other: Maximal exercise test · Other: Endothelial dysfunction assessment · Other: Arterial stiffness assessment

  • Patients with CF with moderate obstruction severity

    In CF children with moderate obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.

    Other: Maximal exercise test · Other: Endothelial dysfunction assessment · Other: Arterial stiffness assessment

Interventions

  • OtherMaximal exercise test

    The maximal exercise test will be performed on an electronically braked bicycle ergometer.

  • OtherEndothelial dysfunction assessment

    Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.

  • OtherArterial stiffness assessment

    Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.

06

What researchers measure

Primary outcomes

  1. Maximal exercise capacity

    The maximal exercise test will be performed on an electronically braked bicycle ergometer using the Godfrey protocol. The peak work capacity (Wzirve) measurement will be expressed as a percentage of normal values.

    Time frame: Maximal exercise test will be performed on the first day

  2. Endothelial dysfunction

    Endothelial dysfunction will be determined by intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, Vascular endothelial growth factor (VEGF), Endothelin-1 (ET-1). Blood samples will be collected.

    Time frame: Endothelial dysfunction assessment will be performed on the first day

  3. Arterial stiffness

    Arterial stiffness, oscillometric pulse wave velocity (PWV) (m s - 1) and augmentation index (AI@75) (%) will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.

    Time frame: Arterial stiffness assessment will be performed on the first day

07

Study locations

1 site
  • Hacettepe University, Faculty of Physical Therapy and Rehabilitation
    Ankara, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04259983
Lead sponsor
Hacettepe University
Responsible party
Senem Simsek (Principal Investigator, Hacettepe University) — Principal investigator
First posted
Feb 7, 2020
Start date
Apr 11, 2022
Primary completion
Dec 8, 2022
Completion
May 2, 2023
Last update
Dec 6, 2023

Study contacts

Deniz Inal-Ince, PhD
study director · Hacettepe University
Senem Simsek, MSc
principal investigator · Hacettepe University
Elmas Ebru Gunes-Yalcin, PhD
principal investigator · Hacettepe University
Murat Timur Budak, PhD
principal investigator · Hacettepe University
Nagehan Emiralioglu, PhD
principal investigator · Hacettepe University
Aslihan Cakmak, MSc
principal investigator · Hacettepe University
Yasemin Kartal, MSc
principal investigator · Hacettepe University
Suna Sabuncuoğlu, PhD
principal investigator · Hacettepe University
Meltem Akgül Erdal, MSc
principal investigator · Hacettepe University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion